Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
To evaluate the safety and efficacy of zanubrutinib in the treatment of antiphospholipid syndrome with secondary thrombocytopenia in 10 patients.
Epistemonikos ID: d1b1ac7a291ac410e9cc963c090251be3b0aa2c6
First added on: May 10, 2024